Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (10144)	1/26/2004 7:36:43 PM
From: Gary Mohilner	Respond to of 52153

Peter, I've also looked into GMED and have invested. I agree that Dr. Moskowitz is strictly using approved drugs developed by others, however, I gather that he has numerous patents on his applications. I believe his patents put him in a position that should see the company well paid if these applications are proven and approved by the FDA and other similar organizations. I've seen posts from at least a few patients who seem to have had substantial benefit from some of Dr. Moskowitz's protocols. In the past he's been after diseases that would be difficult to run trials on, such as SARS and West Nile Virus. Today he announced a trial against the common cold, this should rapidly achieve results, even if most of it is anecdotal. I don't believe that GMED will conduct FDA approved trials without the participation of partners, probably the companies already selling the approved drugs for other applications. I believe this could happen because I think they'd be better off working with GMED then being sued by them for violating their patents. I certainly agree with you that there's a risk in pink sheet stocks, however there can also be a tremendous reward. I believe Dr. Moskowitz has some good ideas, and I think he's building an interesting business around it. Gary